08-07-2021, 06:33 AM
I would be cautious chasing PFE with much money here. Sure their revenues will be amazing for 2021/22 but it's a hard act to follow. Maybe these vaccine makers do have room to go higher but some quarter soon the phase 3 stable will be what matters to the market. PFE is not a biotech startup that runs higher on phase one hopes.